MAPK6-DT

Across TCGA pan-cancer cohorts, MAPK6-DT RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MAPK6-DT’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MAPK6-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAPK6-DT is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

HNSC, THCA, and LUSC are the cancer types where MAPK6-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAPK6-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.515	<.001	10	view →
THCA	Female	All	−0.289	<.001	10	view →
LUSC	Female	All	+0.644	<.001	6	view →
LIHC	All	All	+0.166	.001	4	view →
KIRC	Male	All	−0.112	.006	4	view →
PRAD	All	All	+0.293	<.001	2	view →
LUAD	Male	II,III,IV	+0.251	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MAPK6-DT–HNSC

Open the HNSC breakdown →